<DOC>
	<DOCNO>NCT00003225</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness amifostine plus irinotecan treating patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Amifostine Plus Irinotecan Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity profile irinotecan amifostine administer together patient metastatic colorectal cancer . II . Assess total dose irinotecan receive per 6 week course patient . III . Determine incidence irinotecan-induced leukopenia , neutropenia , diarrhea patient . V. Determine response rate patient population . OUTLINE : This open label study . Amifostine administer 10 minute IV infusion . Irinotecan administer IV infusion 15 minute completion amifostine . Treatment repeat every 2 week 6 week . This 6 week course repeat absence disease progression . Treatment may delay 2 week course allow recovery toxic effect . Patients follow end study 30 day study . PROJECTED ACCRUAL : There 25-30 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>18 year age old ECOG 02 Life expectancy least 12 week Pathologically confirm diagnosis metastatic colorectal cancer Measureable disease Have receive therapy cancer within 4 week enrollment study Prior radiation therapy pelvis treatment colorectal cancer allow . Radiation therapy deliver elsewhere allow long patient treatment least six week measurable lesion present outside radiation field Pretreatment granulocyte count &gt; 1500/mm3 , hemoglobin &gt; 9.0 g/dL ( without transfusion ) , platelet count &gt; 100,000/um Serum creatinine &lt; 2.0 mg/dL Adequate hepatic function document serum bilirubin &lt; 2.0 mg/dL regardless whether patient liver involvement secondary tumor . AST must &lt; 3x upper limit normal unless liver involved tumor , case AST must &lt; 5x institutional upper limit normal Prior therapy Irinotecan Patients active uncontrolled infection Patients psychiatric disorder would interfere consent followup Patients history myocardial infarction within previous six month , congestive heart failure , cerebrovascular disease History prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree least five year Presence clinically apparent central nervous system metastases carcinomatous meningitis Patients uncontrolled diabetes mellitus Any sever concurrent disease , judgment investigator , would make patient inappropriate entry study Patients unable stop take antihypertensive medication 24 hour prior administration Ethyol ( x 1 day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>